



## Intercept to Announce Fourth Quarter and Full Year 2022 Financial Results on March 2, 2023

February 23, 2023

MORRISTOWN, N.J., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its fourth quarter and full-year 2022 financial results on Thursday, March 2, 2023. The announcement will be followed by a conference call and audio webcast at 8:30 a.m. ET.

Participants can access the conference call live via webcast which will be available on the investor page of the company's website at <http://ir.interceptpharma.com>. Participants who wish to ask a question may register [here](#) to receive dial-in numbers and a unique pin to join the call. While not required, it is recommended you join 10 minutes prior to the event's start. A replay of the call will be available on Intercept's website following the completion of the call.

### About Intercept

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH) and severe alcohol-associated hepatitis (sAH). For more information, please visit [www.interceptpharma.com](http://www.interceptpharma.com) or connect with the Company on [Twitter](#) and [LinkedIn](#).

### Contact

For more information about Intercept, please contact:

Investor inquiries: [investors@interceptpharma.com](mailto:investors@interceptpharma.com)

Media inquiries: [media@interceptpharma.com](mailto:media@interceptpharma.com)



Source: Intercept Pharmaceuticals, Inc.